menu
    • menu
    [{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Galantamine Benzoate","moa":"AchE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Not Applicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Galantamine Benzoate","moa":"AchE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Not Applicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Galantamine Benzoate","moa":"AChE","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Not Applicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Galantamine Benzoate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Alpha Cognition \/ Spartan Capital Securities","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Securities LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alpha Cognition \/ Spartan Securities LLC","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Spartan Securities LLC"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Alpha Cognition \/ Spartan Capital Securities","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Galantamine Benzoate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Not Applicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Spartan Capital Securities","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Galantamine Benzoate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Galantamine Benzoate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Undisclosed"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Galantamine Benzoate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alpha Cognition \/ Not Applicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Galantamine Benzoate","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Alpha Cognition","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Alpha Cognition \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alpha Cognition \/ Not Applicable"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"The Benchmark Company, LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Galantamine Benzoate","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Alpha Cognition","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Alpha Cognition \/ The Benchmark Company, LLC","highestDevelopmentStatusID":"12","companyTruncated":"Alpha Cognition \/ The Benchmark Company, LLC"},{"orgOrder":0,"company":"Alpha Cognition","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Galantamine Benzoate","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Alpha Cognition","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Alpha Cognition \/ Titan Partners Group","highestDevelopmentStatusID":"12","companyTruncated":"Alpha Cognition \/ Titan Partners Group"}]

    Find Clinical Drug Pipeline Developments & Deals for Galantamine Benzoate

    Menu

    Galantamine Benzoate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Titan Partners Group

                            Deal Size : $50.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Alpha Cognition Prices $50M Upsized Public Offering and Nasdaq Listing

                            Details : The Company intends to use the proceeds towards the commercialization and launch of Zunveyl (benzgalantamine) for the treatment of mild-to-moderate Alzheimer’s Disease.

                            Brand Name : Zunveyl

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 12, 2024

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Titan Partners Group

                            Deal Size : $50.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : The Benchmark Company, LLC

                            Deal Size : $4.5 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Alpha Cognition Completes $4.5M Convertible Note and Bridge Financing

                            Details : The proceeds from the financing will be utilized to continue commercialization work for the Company’s recently approved Zunveyl (benzgalantamine), indicated for the treatment of Alzheimer's disease.

                            Brand Name : Zunveyl

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 24, 2024

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : The Benchmark Company, LLC

                            Deal Size : $4.5 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease

                            Details : ZUNVEYL, a prodrug of AD treatment galantamine and an acetylcholinesterase inhibitor (AChEI), is postulated to exert its therapeutic effect by preventing the breakdown of acetylcholine.

                            Brand Name : Zunveyl

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 29, 2024

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $6.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering

                            Details : The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.

                            Brand Name : ALPHA-1062

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 22, 2023

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $6.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer...

                            Details : ALPHA-1062 (benzgalantamine), AChE inhibitor delayed-release oral tablet formulation. Currently being evaluated in the Phase III clinical trial studies for the treatment of mild-to-moderate Alzheimer’s Disease.

                            Brand Name : ALPHA-1062

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 07, 2023

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $6.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering

                            Details : The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.

                            Brand Name : ALPHA-1062

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 04, 2023

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $6.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Spartan Capital Securities

                            Deal Size : $6.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Alpha Cognition Announces Third Closing of Private Placement and Continuation of the Offering

                            Details : The company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.

                            Brand Name : ALPHA-1062

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 08, 2023

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Spartan Capital Securities

                            Deal Size : $6.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $97.8 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering

                            Details : The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.

                            Brand Name : ALPHA-1062

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 16, 2023

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $97.8 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alpha Cognition Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Al...

                            Details : ALPHA-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild-to-moderate Alzheimer’s Disease.

                            Brand Name : ALPHA-1062

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 27, 2023

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed

                            Alpha Cognition

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $1.3 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering

                            Details : The Company expects to use the net proceeds for research and development of ALPHA-1062 (benzgalantamine), a prodrug of an approved acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer's Disease.

                            Brand Name : ALPHA-1062

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 31, 2023

                            Lead Product(s) : Galantamine Benzoate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : $1.3 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth